Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 2013. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in share interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of insider trading activity rather than a financial performance report.
Material Changes
The filing details a specific transaction on June 11, 2013, involving Mr. P C Thomson and his connected person, Mrs. K Thomson. Through the Company's ShareReward Plan, they acquired a total of 4 Ordinary Shares (2 shares via personal contribution and 2 shares via the Company's matching element) at a price of 1658.92 pence per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly adheres to the Disclosure and Transparency Rule 3.1.4R(1)(c) regarding the notification of director transactions.
Investor Verification Points
- Verify the total number of shares acquired by Mr. P C Thomson and Mrs. K Thomson (4 shares total).
- Confirm the transaction price of 1658.92 pence per Ordinary Share.
- Note the transaction date of June 11, 2013, and the notification date of June 12, 2013.
- Understand that this filing does not contain financial performance data for the period.